Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) Stirring Excitement at Technical Support

Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) Stirring Excitement at Technical Support

SHARE

Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) is a micro-cap stock ostensibly in the pet cancer space. PTLF has been in a major fight for support in recent trade, but may yet be able to generate some excitement. They are trying to get that excitement going with the latest announcement that it is back on the road to bring its “message of hope to pet owners in the fight against cancer in our companion animals. While the presentations are targeted to high net worth investors, the Company has found that most of these investors share our passion for our furry friends. They understand our mission to bring an all-natural and cost-effective treatment of cancer through the necessary clinical trials and to make our patent pending product, VitalzulTM, an integral part of cancer treatment.”

Traders will note 11% tacked on to share pricing for PTLF in the past week, a rally that has pushed up against longer standing distributive pressure in the stock. This is emblematic of the stock. PTLF has evidenced sudden upward volatility on many prior occasions. In addition, PTLF has seen interest climb, with an increase in recent trading volume of 310% above its longer run average levels.

Petlife Pharmaceuticals Inc (OTCMKTS:PTLF) frames itself as a company that engages in the research, development, sale, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases in the United States. The company’s product includes Vitalzul, a line of over-the-counter nutraceuticals, infused dog and cat treats, and prescription strength pharmaceuticals for pets. Petlife Pharmaceuticals, Inc. is based in Hancock, Maryland.

PetLife Pharmaceuticals, Inc. is a registered U.S. Veterinary Pharmaceutical company whose mission is to bring its scientifically proven, bioactive medication and nutraceuticals – Vitalzul – to the world of veterinary oncology. PTLF specializes in the research, development, sales and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis.

Find out when $PTLF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, PTLF is trying to stoke some new excitement, with management heading back out on the road to spread its message and core vision.

According to the company’s most recent release, “VitalzulTM is based on the venom of the Caribbean Blue Scorpion, which for hundreds of years has been known to have an effect on many varieties of tumors. Having completed several studies, PetLife is currently seeking funding to continue these pre-INAD (Investigational New Animal Drug) studies in preparation for a timely filing with the United States Food & Drug Administration (“FDA”) for a complete Oncology Clinical / Regulatory Development plan. The path through the FDA process is anticipated to take 18-24 months for completion… Clifford Price, VP of Marketing for PetLife Pharmaceuticals, will be presenting to investors in Santa Barbara on Aug. 2, 2017, and to investors in Beverly Hills on August 8, 2017.”

“These presentations create a unique opportunity for investors to be a part of a changing paradigm in the treatment of cancer for both pets and humans,” stated Mr. Price.

At this time, carrying a capital value in the market of $11.36M, PTLF has virtually no cash on the books, which stands against about $845K in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. As more color becomes clear on the name, we will review the situation and update our take. For continuing coverage on shares of $PTLF stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Disclosure: we hold no position in $PTLF, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter